Sign up
Healthed-White-on-Blue
Gallagher,James

Mr James Gallagher

BBC Health and science correspondent. Presenter of The Second Genome and The Inflamed Mind. Contrary to popular opinion my middle name is not Tiberius.

More from this expert

Image_Paul-Van-Buynder0
Videos iconVideos

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

feature-image-e1512457124620
Monographs iconMonographs

Update on Herpes Zoster

This article discusses herpes zoster, the condition and its complications as well as the benefits, risks and challenges associated with the herpes zoster vaccine.

Image_Paul-Van-Buynder0
Videos iconVideos

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Image_Paul-Van-Buynder0

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

By Prof Paul Van Buynder
Videos iconVideos
feature-image-e1512457124620

Update on Herpes Zoster

This article discusses herpes zoster, the condition and its complications as well as the benefits, risks and challenges associated with the herpes zoster vaccine.

By A/Prof John Litt AM, Prof Tony Cunningham AO, Prof Paul Van Buynder
Monographs iconMonographs
shutterstock_2137348775

Shingles – Why it is a serious problem and why the new vaccine is a good development

Post shingles, QOL is significantly and permanently reduced.

By Prof Paul Van Buynder
Podcasts iconPodcasts
An,African,Doctor,Holding,A,Covid,19,Vaccine,Vial,In

COVID update – Tackling booster confusion, the next wave & non-mRNA jabs

Which booster when? Is bivalent or monovalent better? Plus when non-mRNA boosters are appropriate

By Prof Paul Van Buynder
Podcasts iconPodcasts
Image_Paul-Van-Buynder0

Bivalent original/omicron pre-filled syringe for COVID-19 vaccination

In this Product Explainer, Public Health Physician Prof Paul Van Buynder explains the role of the Bivalent Original/Omicron BA.4-5 pre-filled syringe COVID-19 vaccine and provides an update on the situation in aged care, and how boosters can assist in protecting the community against symptomatic infection and severe disease (5 mins).

By Prof Paul Van Buynder
Videos iconVideos
Image_Paul-Van-Buynder0

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

By Prof Paul Van Buynder
Videos iconVideos

Discover

Healthed

CPD platform

Upcoming Healthed Webcast

Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture

Tuesday 9th June, 7pm - 9pm AEST

Speaker

Dr Philip Tong

Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney

What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.

Register for webcast